文献速递胃肠外科围术期管理与 ERAS

阿维莫泮在已建立的ERAS项目中仍对结直肠手术患者有效

Alvimopan retains efficacy in patients undergoing colorectal surgery within an established ERAS program.
PubMed 文献 · Surg Endosc · 2022-01-18

这项单中心回顾性队列分析纳入192例结直肠切除患者,按是否接受阿维莫泮和/或利多卡因分为AL、Al、aL、al四组。主要终点首次排便或出院的中位时间组间有显著差异(p=0.001),AL组39.4小时优于aL组54.0小时(p=0.003)和al组55.4小时(p=0.001);AL和Al组住院时间较aL组显著缩短1.8天(p<0.001)。

要点

  • 阿维莫泮联合利多卡因组首次排便或出院中位时间最短(39.4小时)。
  • 阿维莫泮联合利多卡因组较单用利多卡因组住院时间缩短1.8天。
  • 在已建立的ERAS项目中,阿维莫泮仍改善胃肠道恢复时间并缩短住院时间。

核心结论

  • 在已建立的ERAS项目中,阿维莫泮治疗显著改善胃肠道恢复时间并缩短住院时间。
  • 接受阿维莫泮和利多卡因联合治疗组在胃肠道恢复时间和住院时间上改善最大。

研究设计与样本

  • 430例患者中192例纳入最终评估,分为AL组(n=93)、Al组(n=34)、aL组(n=44)、al组(n=21)。

主要发现

  • 主要终点首次排便或出院中位时间组间有显著差异(p=0.001)。
  • AL组39.4小时 vs aL组54.0小时(p=0.003)。
  • AL组39.4小时 vs al组55.4小时(p=0.001)。
  • Al组44.9小时 vs al组55.4小时(p=0.01)。
  • AL和Al组住院时间较aL组显著缩短1.8天(p<0.001)。

关键数值与推荐

  • 主要终点为首次排便或出院的中位时间,以先发生者为准。
  • 次要终点为住院时间。
  • 利多卡因对阿片类药物使用的减少作用很小。

临床怎么用

  • 在已建立的ERAS项目中,可考虑使用阿维莫泮以改善结直肠手术患者胃肠道恢复时间并缩短住院时间。
  • 阿维莫泮联合利多卡因方案在胃肠道恢复时间和住院时间上改善最大。

局限性

  • 原文自述为单中心、回顾性队列分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Post-operative ileus and delayed return of gastrointestinal function are complications seen frequently in patients undergoing colorectal surgery. Many enhanced recovery after surgery protocols include alvimopan to inhibit the effects of opiates in the gastrointestinal tract and lidocaine to augment analgesics. Limited data exist regarding alvimopan's efficacy in opiate-sparing regimens. METHODS: This single-center, retrospective cohort analysis was conducted in a randomly selected population of adult patients undergoing colorectal resection between February 2018 and October 2019. Patients meeting inclusion criteria were divided into four groups dependent upon whether or not they received alvimopan (A or a) and/or lidocaine (L or l). The primary endpoint in this study was median time to first bowel movement or discharge, whichever came first. Our secondary endpoint was length of stay. RESULTS: Of the 430 patients evaluated, a total of 192 patients were included in the final evaluation in the following groups: AL (n = 93), Al (n = 34), aL (n = 44), and al (n = 21). A significant difference was found among the groups for the primary outcome of median time to bowel movement or discharge (p = 0.001). Three subsequent pair-wise comparisons resulted in a significant difference in the primary outcome: group AL 39.4 h vs. group aL 54.0 h (p = 0.003), group AL 39.4 h vs. group al 55.4 h (p = 0.001), and group Al 44.9 h vs. group al 55.4 h (p = 0.01). Length of stay was significantly reduced by 1.8 days in groups AL and Al compared to group aL (p < 0.001). CONCLUSION: Treatment with alvimopan resulted in a significant improvement in time to GI recovery and decreased length of stay in an established ERAS program. While lidocaine's reduction in opiates was minimal, the group receiving both alvimopan and lidocaine had the greatest reduction in time to GI recovery and length of stay.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Brown S, McLoughlin J, Russ A, et al. Alvimopan retains efficacy in patients undergoing colorectal surgery within an established ERAS program. Surg Endosc. 2022. PMID: 35043232. doi:10.1007/s00464-021-08928-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。